Growth hormone secretagogues: classes, signals, and evidence limits

Many early secretagogue studies measure growth hormone pulses, area under the concentration curve, IGF-1, pharmacokinetics, or receptor selectivity. Those outcomes can show target engagement. They do not automatically prove changes in recovery, muscle, fat, sleep, longevity, injury healing, or quality of life.

To evaluate a broader outcome claim, look for a controlled human study that enrolled the relevant population and measured that outcome for an adequate period. Keep biomarker, body-composition, symptom, functional, and clinical endpoints in separate columns.

Development codes, modified sequences, attachment groups, and vendor shorthand can cause one online name to point to more than one chemical identity. The phrase 'CJC-1295 no DAC' is a common example of unstable non-primary terminology. A comparison should start with an exact sequence, modification, registry identifier, or primary-paper definition, not a storefront label.

When identity cannot be resolved, the correct editorial conclusion is that the comparison is indeterminate. This batch therefore replaces a planned DAC-versus-no-DAC page with a nomenclature guide rather than manufacture a false head-to-head evidence base.

A useful summary names the compound, pathway, model or population, design, measured outcome, duration, and limitations. It distinguishes experimental findings from approved indications and checks official records for current regulatory status. It also reports adverse events and discontinuations when human data are available.

This page is not a protocol. It omits combinations, timing, dose, reconstitution, administration, and sourcing. Endocrine signaling is clinically consequential, and an educational taxonomy cannot substitute for evaluation by a qualified clinician.